The role of EZH2 in tumour progression

C. J. Chang; M. C. Hung

doi:10.1038/bjc.2011.551

The role of EZH2 in tumour progression

C. J. Chang, M. C. Hung

Molecular & Cellular Oncology

Research output: Contribution to journal › Review article › peer-review

286 Scopus citations

Abstract

Accumulated evidence shows that EZH2 is deregulated in a wide range of cancer types, and it has a crucial role in stem cell maintenance and tumour development. Therefore, blocking EZH2 expression or activity may represent a promising strategy for anticancer treatment. In this review, we address the current understanding of the mechanisms underlying EZH2 regulation alongside the function of EZH2 gene targets that are involved in cancer progression. Finally, we will describe cancer therapies that target EZH2 or its downstream cascades, which could potentially reverse the oncogenic and stemness properties of the tumour cells to suppress cancer progression and recurrence.

Original language	English (US)
Pages (from-to)	243-247
Number of pages	5
Journal	British journal of cancer
Volume	106
Issue number	2
DOIs	https://doi.org/10.1038/bjc.2011.551
State	Published - Jan 17 2012

Keywords

EZH2
Polycomb proteins
histone methyltransferase

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/bjc.2011.551

Cite this

@article{7a5f3b1705634a95b8fc11593f226491,

title = "The role of EZH2 in tumour progression",

abstract = "Accumulated evidence shows that EZH2 is deregulated in a wide range of cancer types, and it has a crucial role in stem cell maintenance and tumour development. Therefore, blocking EZH2 expression or activity may represent a promising strategy for anticancer treatment. In this review, we address the current understanding of the mechanisms underlying EZH2 regulation alongside the function of EZH2 gene targets that are involved in cancer progression. Finally, we will describe cancer therapies that target EZH2 or its downstream cascades, which could potentially reverse the oncogenic and stemness properties of the tumour cells to suppress cancer progression and recurrence.",

keywords = "EZH2, Polycomb proteins, histone methyltransferase",

author = "Chang, {C. J.} and Hung, {M. C.}",

note = "Funding Information: The authors are grateful for the support of the National Breast Cancer Foundation, Inc.",

year = "2012",

month = jan,

day = "17",

doi = "10.1038/bjc.2011.551",

language = "English (US)",

volume = "106",

pages = "243--247",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - The role of EZH2 in tumour progression

AU - Chang, C. J.

AU - Hung, M. C.

N1 - Funding Information: The authors are grateful for the support of the National Breast Cancer Foundation, Inc.

PY - 2012/1/17

Y1 - 2012/1/17

N2 - Accumulated evidence shows that EZH2 is deregulated in a wide range of cancer types, and it has a crucial role in stem cell maintenance and tumour development. Therefore, blocking EZH2 expression or activity may represent a promising strategy for anticancer treatment. In this review, we address the current understanding of the mechanisms underlying EZH2 regulation alongside the function of EZH2 gene targets that are involved in cancer progression. Finally, we will describe cancer therapies that target EZH2 or its downstream cascades, which could potentially reverse the oncogenic and stemness properties of the tumour cells to suppress cancer progression and recurrence.

AB - Accumulated evidence shows that EZH2 is deregulated in a wide range of cancer types, and it has a crucial role in stem cell maintenance and tumour development. Therefore, blocking EZH2 expression or activity may represent a promising strategy for anticancer treatment. In this review, we address the current understanding of the mechanisms underlying EZH2 regulation alongside the function of EZH2 gene targets that are involved in cancer progression. Finally, we will describe cancer therapies that target EZH2 or its downstream cascades, which could potentially reverse the oncogenic and stemness properties of the tumour cells to suppress cancer progression and recurrence.

KW - EZH2

KW - Polycomb proteins

KW - histone methyltransferase

UR - http://www.scopus.com/inward/record.url?scp=84856466661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856466661&partnerID=8YFLogxK

U2 - 10.1038/bjc.2011.551

DO - 10.1038/bjc.2011.551

M3 - Review article

C2 - 22187039

AN - SCOPUS:84856466661

SN - 0007-0920

VL - 106

SP - 243

EP - 247

JO - British journal of cancer

JF - British journal of cancer

IS - 2

ER -

The role of EZH2 in tumour progression

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this